Business
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays
About this update from Quidelortho Corporation
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nQuidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler has retired from the Company’s Board of Directors effective June 10, 2020. Mr. Schuler has served on the board since February 2006.\n\n\n“As a member of our Board for the last 14 years, Jack leaves a legacy of market leadership, a vastly expanded international footprint, rapid growth and a strong R&D presence. Today, Quidel is one of the leading diagnostic players in the point-of-care space, which was built through the organic development of franchise brands like Sofia® and strategic acquisitions like Diagnostic Hybrids, BioHelix, and the Alere Assets,” said Douglas Bryant, president and CEO of Quidel. “I personally want to thank Jack for his many years of service to Quidel, during which we have seen tremendous shareholder value creation as our market cap grew from $300 million to $7 billion. His influence on our company is indelible, and we are grateful for his long-term support and guidance. On behalf of Quidel, we thank him, and certainly wish him well.”\n\n\n“As I approach my 80th birthday, I feel now is the time to retire from this great company’s Board,” said Jack Schuler. “Quidel will continue to be a leader in point of care testing and play a big role in the world’s need to control respiratory viruses.”\n\n\nAbout Quidel Corporation\n\n\nQuidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, lyme, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's Triage® system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety o...